Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function

Psychopharmacology

Volumn 222, Issue 2, 2012, Pages 185-202

  Tota, Santosh Kumar ^a   Hanif, Kashif ^a   Kamat, Pradeep Kumar ^a   Najmi, Abul Kalam ^b   Nath, Chandishwar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Angiotensin receptors; Candesartan; Memory; PD123,319; Scopolamine

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; NITRITE; SCOPOLAMINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN METABOLISM; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENERGY METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; HIPPOCAMPUS; LASER DOPPLER FLOWMETRY; MALE; MAZE TEST; MOUSE; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SPATIAL MEMORY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AVOIDANCE LEARNING; BENZIMIDAZOLES; CEREBRAL CORTEX; HIPPOCAMPUS; HYPERTENSION; IMIDAZOLES; LASER-DOPPLER FLOWMETRY; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MUSCARINIC ANTAGONISTS; OXIDATIVE STRESS; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SCOPOLAMINE HYDROBROMIDE; TETRAZOLES;

EID: 84864474059     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2639-7     Document Type: Article

References (63)

1. Awasthi H, Tota S, Hanif K, Nath C, Shukla R (2010) Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sci 86:87-94
2. Baranov D, Armstead WM (2003) Selective blockade of AT1 receptor attenuates impairment of hypotensive autoregulation and improves cerebral blood flow after brain injury in the newborn pig. Anesthesiology 99:1118-24
3. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Naylor RJ (1989) Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 491:136-43
4. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, Williams TJ (1990) Angiotensin II inhibits cortical cholinergic function: Implications for cognition. J Cardiovasc Pharmacol 16:234-8
5. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ (1991) Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. Neuroreport 2:351-3
6. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529
7. Bassant MH, Jazat F, Lamour Y (1993) Tetrahydroaminoacridine and physostigmine increase cerebral glucose utilization in specific cortical and subcortical regions in the rat. J Cereb Blood Flow Metab 13:855-64
8. Carey RM, Jin XH, Siragy HM (2001) Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 14:98S-102S
9. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997) A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-33
10. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26:699-708
11. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-7
12. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
13. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R (2004) The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24:467-74
14. Ertl G, Hu K (2001) Anti-ischemic potential of drugs related to the renin-angiotensin system. J Cardiovasc Pharmacol 37(Suppl 1): S11-20
15. Estrup TM, Paulson OB, Strandgaard S (2001) No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation. J Renin Angiotensin Aldosterone Syst 2:188-92
16. Faure S, Bureau A, Oudart N, Javellaud J, Fournier A, Achard JM (2008) Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens 26:2008-15
17. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF (2011) Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11:1193-206
18. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P (2003) Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 17:781-5
19. Fukuda K, Hirooka K, Mizote M, Nakamura T, Itano T, Shiraga F (2011) Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 51:3629-38
20. Gard PR (2002) The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 438:1-14
21. Giacobini E (1990) The cholinergic system in Alzheimer disease. Prog Brain Res 84:321-32
22. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem 126:131-8
23. Hanif K, Snehlata PMC, Arif E, Biswas P, Fahim M, Pasha MA, Pasha S (2009) Effect of 3-thienylalanine-ornithine-proline, new sulfurcontaining angiotensin-converting enzyme inhibitor on blood pressure and oxidative stress in spontaneously hypertensive rats. J Cardiovasc Pharmacol 53:145-50
24. Hasselmo ME (2006) The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16:710-5
25. Hoglund AU, Hamilton C, Lindblom L (2000) Effects of microdialyzed oxotremorine, carbachol, epibatidine, and scopolamine on intraspinal release of acetylcholine in the rat. J Pharmacol Exp Ther 295:100-4
26. Honer WG, Prohovnik I, Smith G, Lucas LR (1988) Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8:635-41
27. Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M (2009) Continuous activation of renin-angiotensin system impairs cognitive function in renin/ angiotensinogen transgenic mice. Hypertension 53:356-62
28. Jeong EJ, Lee KY, Kim SH, Sung SH, Kim YC (2008) Cognitiveenhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine-treated mice. Eur J Pharmacol 588:78-84
29. Jones RW, Wesnes KA, Kirby J (1991) Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci 640:241-4
30. Kapogiannis D, Mattson MP (2011) Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 10:187-98
31. Kehoe PG (2003) The renin-angiotensin-aldosterone system and Alzheimer s disease? J Renin Angiotensin Aldosterone Syst 4:80-93
32. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease-friend or foe? Trends Neurosci 32:619-28
33. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2011) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340:b5465
34. Liu JJ, Li DL, Zhou J, Sun L, Zhao M, Kong SS,Wang YH, Yu XJ, Zhou J, Zang WJ (2011) Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis 16:94-103
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75
36. Lu Q, Zhu YZ, Wong PT (2005) Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 16:1963-7
37. Maul B, von Bohlen und Halbach O, Becker A, Sterner-Kock A, Voigt JP, Siems WE, Grecksch G, Walther T (2008) Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J Mol Med 86:563-71
38. Molchan SE, Matochik JA, Zametkin AJ, Szymanski HV, Cantillon M, Cohen RM, Sunderland T (1994) A double FDG/PET study of the effects of scopolamine in older adults. Neuropsychopharmacology 10:191-8
39. Mosimann R, Imboden H, Felix D (1996) The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Biol Rev Camb Philos Soc 71:545-59
40. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M (2001) Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42:1441-5
41. Nishimura Y, Ito T, Saavedra JM (2000) Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-86
42. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M, Hellstrom-Lindahl E, Bjurling P et al (1992) Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 13:747-58
43. Ogawa M, Magata Y, Ouchi Y, Fukuyama H, Yamauchi H, Kimura J, Yonekura Y, Konishi J (1994) Scopolamine abolishes cerebral blood flow response to somatosensory stimulation in anesthetized cats: PET study. Brain Res 650:249-52
44. Plaschke K, Hoyer S (1993) Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci 11:477-83
45. Raghavendra V, Chopra K, Kulkarni SK (1998) Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 32:417-21
46. Raghavendra V, Chopra K, Kulkarni SK (2001) Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 35:65-9
47. Saito K, Honda S, Egawa M, Tobe A (1985) Effects of bifemelane hydrochloride (MCI-2016) on acetylcholine release from cortical and hippocampal slices of rats. Jpn J Pharmacol 39:410-4
48. Sakurai T, Kato T, Mori K, Takano E, Watabe S, Nabeshima T (1998) Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: An in vivo microdialysis study. Neurosci Lett 246:69-72
49. Savaskan E (2005) The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2:29-35
50. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F (2001) Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22:541-6
51. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA (2008) Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 70:1858-66
52. Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C (2007) Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav 86:797-805
53. Sharma D, Puri M, Tiwary AK, Singh N, Jaggi AS (2011) Antiamnesic effect of stevioside in scopolamine-treated rats. Indian J Pharmacol 42:164-7
54. Shepherd J, Bill DJ, Dourish CT, Grewal SS, McLenachan A, Stanhope KJ (1996) Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory. Psychopharmacology (Berl) 126:206-18
55. Spignoli G, Pepeu G (1987) Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27:491-5
56. Tota S, Kamat PK, Awasthi H, Singh N, Raghubir R, Nath C, Hanif K (2009) Candesartan improves memory decline in mice: Involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 199:235-40
57. Tota S, Awasthi H, Kamat PK, Nath C, Hanif K (2010) Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209:73-9
58. Tota S, Kamat PK, Shukla R, Nath C (2011) Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res 221:207-215
59. Tota S, Kamat PK, Saxena G, Hanif K, Najmi AK, Nath C (2012) Central angiotensin converting enzyme facilitates memory impairment in intracerebroventricular streptozotocin treated rats. Behav Brain Res 226:317-30
60. Tsukada H, Kakiuchi T, Ando I, Ouchi Y (1997) Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: A positron emission tomography study in anaesthetized monkeys. J Pharmacol Exp Ther 281:1408-14
61. Wang C, Smith RL (1975) Lowry determination of protein in the presence of Triton X-100. Anal Biochem 63:414-7
62. Wright JW, Harding JW (2011) The brain RAS and Alzheimer's disease. Exp Neurol 223:326-33
63. Wyper D, Teasdale E, Patterson J, Montaldi D, Brown D, Hunter R, Graham D, McCulloch J (1993) Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. Br J Radiol 66:23-7